Adult AIDS Clinical Trials Unit: Component C4: Developmental Pharmacology. This application seeks to extend the goals of the Core Pharmacology (Component C.2) Laboratory to include the following specific aims; 1. To establish a comprehensive program to investigate the clinical pharmacology of current and newly introduced drugs with potential value for the treatment of Human Immunodeficiency Virus (HIV) infection, opportunistic infections and malignancies. 2. To conduct clinical protocols specifically designed , or nested within larger studies, to investigate; clinically important drug interactions, pharmacokinetic/pharmacodynamic characteristics among subpopulations of HIV-infected individuals, the influence of concurrent disease on antiretroviral disposition.. 3. To integrate the results obtained from an in vitro hollow fiber perfusion model which correlates extracellular and intracellular concentrations of antiretroviral agents (parent and metabolites) with the development of clinical protocols to assess the potential mechanisms of implementing a therapeutic drug monitoring program to guide chronic anti- HIV therapy. 4. To investigate the extent of blood component distribution of antiretroviral agents and their relationship to determining the appropriate biologic matrix for future therapeutic drug monitoring studies. To achieve these aims a series of clinical and in vitro studies will be conducted with the overall goal of elucidating the relationship between serum concentrations. Intracellular concentrations and comparative assay methodologies to provide a basis for rational therapeutic drug monitoring for chronic anti-HIV therapy.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Gupta, S K; Kitch, D; Tierney, C et al. (2015) Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 16:591-8

Showing the most recent 10 out of 153 publications